A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Inclusion Criteria: Inclusion criteria for cast nephropathy associated with MM: * Subjects must have a confirmed diagnosis of NDMM as per standard IMWG criteria * Subjects must have measurable disease, defined as meeting at least 1 of the following criteria ≤ 14 days prior to registration: * A monoclonal Immunoglobulin (M-protein) concentration on serum protein electrophoresis (SPEP) of ≥ 0.5 g/dL. * Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of ≥ 200 mg/24 hours. * Involved serum free light chain (FLC) level ≥ 10 mg/dL, provided the serum FLC ratio is abnormal. * eGFR must be \<40 ml/min/1.73m2 * Subjects must have histologically confirmed diagnosis of monoclonal gammopathy associated CN by kidney biopsy OR If a kidney biopsy is not available, a percentage of urine albumin excretion (%UAE) \< 25 % AND FLC \> 50 mg/dL Inclusion criteria for other MGRS associated renal diseases * Histologically confirmed diagnosis of MGRS-associated renal disease by kidney biopsy * Presence of monoclonal gammopathy by serum protein electrophoresis, Immunofixation, or Free Light Chain Assay * Evidence of plasma cell dyscrasia by bone marrow biopsy confirming clonal plasma cell population * eGFR \<40 ml/min/1.73m2 or 24h urine total protein \> 1gm Inclusion criteria for both cast nephropathy associated with MM and other MGRS associated renal diseases * Subjects must be ≥ 18 years of age at time of registration. * Subj…